25,389 results match your criteria Atopic Dermatitis


Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.

J Clin Pharmacol 2018 Dec 17. Epub 2018 Dec 17.

Pfizer Inc., Groton, CT, USA.

Atopic dermatitis is a chronic eczematous, pruritic, inflammatory skin condition affecting children and adults. Tofacitinib is a Janus kinase inhibitor. The efficacy, safety, and pharmacokinetics of 2% tofacitinib ointment twice daily have been evaluated in a 4-week phase 2a multisite randomized, double-blind, vehicle-controlled, parallel-group study (NCT02001181) in adult patients with mild to moderate atopic dermatitis and 2% to 20% body surface area (BSA) involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1360DOI Listing
December 2018
1 Read

Could we use the erythema grading of the CADESI4 as a simple instrument for future short-duration clinical trials of dogs with atopic dermatitis?

Authors:
Thierry Olivry

Vet Dermatol 2018 Dec 17. Epub 2018 Dec 17.

Department of Clinical Sciences, College of Veterinary Medicine, NC State University, 1060 William Moore Drive, Raleigh, NC, 27607, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vde.12709DOI Listing
December 2018

The impact of pediatric atopic dermatitis on families: A review.

Pediatr Dermatol 2018 Dec 16. Epub 2018 Dec 16.

Department of Dermatology, University of California San Francisco, San Francisco, California.

Background: Atopic dermatitis (AD) is an extremely common childhood disease, with considerable impact on the quality of life of affected children and their families. While pruritus is the hallmark symptom of this disease, AD has been well-documented to impact patients beyond physical symptoms, resulting in behavior problems, mood disorders, and sleep disturbance.

Objective: This literature review outlines how atopic dermatitis impacts the quality of life of families of children affected by AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.13727DOI Listing
December 2018

Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray.

J Cutan Med Surg 2018 Dec 17:1203475418818082. Epub 2018 Dec 17.

1 Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Purpose:: Topical corticosteroids (TS) are a treatment for atopic dermatitis (AD) and psoriasis (Ps). We assessed whether use of a TS under conditions designed to enhance adherence would be effective in patients who "failed" TS in the outpatient setting.

Methods:: Individuals with treatment-resistant Ps or AD were recruited (AD, n = 12; Ps, n = 12). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475418818082DOI Listing
December 2018

Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study.

Paediatr Drugs 2018 Dec 17. Epub 2018 Dec 17.

Division of Gastroenterology, Departments of Medicine and Pediatrics, Research Institute of the McGIll University Health Centre, 1650 Cedar Avenue C10.145, Montreal, QC, H3G 1A4, Canada.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects both patients and their families. Current therapies often alleviate symptoms but do not prevent or eradicate the disease.

Objectives: Our objective was to determine whether pancreatic enzyme supplementation is an effective and safe treatment in refractory pediatric AD associated with food allergies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40272-018-0321-1DOI Listing
December 2018
1 Read

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report.

JAAD Case Rep 2019 Jan 4;5(1):34-36. Epub 2018 Dec 4.

Comprehensive Eye Care of Central Ohio, Westerville, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.10.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280680PMC
January 2019

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.

J Am Acad Dermatol 2019 Jan 3;80(1):89-98.e3. Epub 2018 Jul 3.

ICON plc, Research Triangle Park, North Carolina.

Background: Safe and efficacious topical treatments are needed for atopic dermatitis (AD).

Objective: We assessed the safety and efficacy of tapinarof cream (2 concentrations and 2 application frequencies) in patients with AD.

Methods: A double-blind, vehicle-controlled, randomized, 6-arm trial (1:1:1:1:1:1) in patients age 12 to 65 years, with body surface area involvement of at least 5% to 35% and an Investigator's Global Assessment score of 3 or higher (moderate to severe) at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.06.047DOI Listing
January 2019

A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch containing ovalbumin.

Biomed Pharmacother 2019 Jan 13;109:1437-1444. Epub 2018 Nov 13.

Division of Chemotherapy, Kindai University, Faculty of Pharmacy, Kowakae 3-4-1, Higashi-Osaka, Osaka 577-8502, Japan. Electronic address:

CCR4 is a chemokine receptor highly expressed by Th2 cells, and regarded as a potential therapeutic target for atopic dermatitis (AD). CCL17 and CCL22 are the CCR4 ligands, and thymic stromal lymphopoietin (TSLP) is shown to promote the expression of CCL17 and CCL22 by dendritic cells. Here, by using dibutyl phthalate (DBP), a TSLP inducer, and a hydrogel patch as a transcutaneous delivery device for ovalbumin, we developed a novel murine AD model and investigated the effect of Compound 22, a CCR4 antagonist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.10.194DOI Listing
January 2019
1 Read

Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.

J Am Acad Dermatol 2018 Dec 11. Epub 2018 Dec 11.

MedImmune, Cambridge, UK.

Background: Tezepelumab (AMG 157/MEDI9929), a first-in-class monoclonal antibody, targets thymic stromal lymphopoietin, a cytokine implicated in atopic dermatitis (AD) pathogenesis.

Objective: Evaluate efficacy and safety of tezepelumab in adults with moderate to severe AD.

Methods: In this phase 2a study (NCT02525094), 113 patients were randomized 1:1 to subcutaneous tezepelumab 280 mg or placebo every 2 weeks, plus Class 3 topical corticosteroids (TCS). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622183305
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2018.11.059DOI Listing
December 2018
4 Reads

The role of the skin microbiome in atopic dermatitis.

Ann Allergy Asthma Immunol 2018 Dec 11. Epub 2018 Dec 11.

Department of Dermatology, University of California, San Diego, CA,. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2018.12.003DOI Listing
December 2018
1 Read

What's new in the treatment of atopic dermatitis?

Dermatol Ther 2018 Nov 22:e12787. Epub 2018 Nov 22.

Department of Health Sciences, Unit of Dermatology, "Magna Graecia" University, Catanzaro, Italy.

Atopic dermatitis (AD) is a pruritic, chronic and inflammatory skin disease, with an usual onset in the pediatric age. Several drugs are used in the treatment of this skin disease. Drugs as steroid, calcineurin inhibitors, and moisturizing creams are widely used in the treatment of this disease but often patients are not satisfied with the obtained results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12787DOI Listing
November 2018
2 Reads

Occupational contact dermatitis to isopropanol-containing disinfectant based on a genetic defect.

Contact Dermatitis 2018 Dec 12. Epub 2018 Dec 12.

Department of Dermatology and Venerology, Medical University of Graz, Austria.

A 52-year-old non-atopic healthy female Caucasian developed severe hand eczema after 13 years of working as a nurse. No recent changes had occurred in her work activities. The bouts of eczema correlated with her occupational activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cod.13197DOI Listing
December 2018

Methods for Assessing Mast Cell Responses to Engineered Nanomaterial Exposure.

Methods Mol Biol 2019 ;1894:31-45

Department of Pharmaceutical Sciences, Colorado Center for Nanomedicine and Nanosafety, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Mast cells are key effector cells in inflammatory and allergic immune responses such as asthma, rhinitis, and atopic dermatitis. Activation of mast cells leads to immediate release of preformed mediators such as histamine and proteases, which can regulate vascular permeability and the function of a number of immune and nonimmune cells. Engineered nanomaterials (ENM) have been utilized for a wide range of applications and introduced into a number of consumer products; yet the consequent increase in human exposure and any potential adverse effects have not been fully evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8916-4_2DOI Listing
January 2019

The immunosuppressant macrolide tacrolimus activates cold-sensing TRPM8 channels.

J Neurosci 2018 Dec 13. Epub 2018 Dec 13.

Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550 San Juan de Alicante, Spain

TRPM8 is a polymodal, non-selective cation channel activated by cold temperature and cooling agents that plays a critical role in the detection of environmental cold. We found that TRPM8 is a pharmacological target of tacrolimus (FK506), a macrolide immunosuppressant with several clinical uses, including the treatment of organ rejection following transplants, treatment of atopic dermatitis and dry eye disease. Tacrolimus is an inhibitor of the phosphatase calcineurin, an action shared with cyclosporine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.1726-18.2018DOI Listing
December 2018
2 Reads

Early Intervention is Important to Prevent Sensitization to New Allergens.

Med Sci (Basel) 2018 Dec 11;6(4). Epub 2018 Dec 11.

Department of Otolaryngology, Osaka Medical College, 2-7 Daigakumachi Takatsuki, Osaka 569-8686, Japan.

We review current management for allergic rhinitis and possible new treatments for this condition. Management of allergic rhinitis includes promotion of protective factors, avoidance of allergens, and possibly immunotherapy. In recent years, the incidence of allergic rhinitis has increased in many countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/medsci6040114DOI Listing
December 2018

Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.

Int J Mol Sci 2018 Dec 10;19(12). Epub 2018 Dec 10.

Division of Dermatology, Department of Clinical Medicine, Medical College of Yanbian University, Yanji 133000, China.

Atopic dermatitis (AD) is a chronic recurrent skin disease dominated by T-helper 2 inflammation. Momelotinib (MMB) is a novel JAK1/JAK2 inhibitor suppressing the signal transduction of multiple pro-inflammatory cytokines. Recent studies indicated that JAK inhibitor could play a therapeutic role in AD disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19123973DOI Listing
December 2018
3 Reads

Relationship of atopic dermatitis with stroke and myocardial infarction: A meta-analysis.

Medicine (Baltimore) 2018 Dec;97(49):e13512

Department of Neurology, Jiangxi Provincial People's Hospital.

Background: Lots of previous reports have suggested a potential association of atopic dermatitis (AD) with stroke and myocardial infarction (MI). However, the result is still controversial, Consequently, we conducted this meta-analysis to estimate the relationship of AD with Stroke and MI.

Methods: PubMed, Embase, and Web of Science databases were searched from inception to June 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013512DOI Listing
December 2018
2 Reads

A20 and ABIN1 suppression of a keratinocyte inflammatory program with a shared single cell expression signature in diverse human rashes.

J Invest Dermatol 2018 Dec 10. Epub 2018 Dec 10.

Department of Dermatology, UCSF and Veterans Affairs Medical Center, San Francisco, California, USA. Electronic address:

Genetic variation in the NFκB inhibitors, ABIN1 and A20, increase risk for psoriasis. While critical for hematopoietic immune cell function, these genes are believed to additionally inhibit psoriasis by dampening inflammatory signaling in keratinocytes. We dissected ABIN1 and A20's regulatory role in human keratinocyte inflammation using an RNA-seq based comparative genomic approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2018.10.046DOI Listing
December 2018

Authors:

Arerugi 2018 ;67(10):1414-1415

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.67.1414DOI Listing
January 2018

[EARLY INTERVENTION FOR THE DEVELOPMENT OF ATOPIC DERMATITIS].

Authors:
Kenta Horimukai

Arerugi 2018 ;67(10):1405-1411

The Jikei University Katsushika Medical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.67.1405DOI Listing
January 2018

[THE BRIEF COMMENTARY ON GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2018].

Authors:
Hidehisa Saeki

Arerugi 2018 ;67(10):1388-1393

Department of Dermatology, Nippon Medical School.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.67.1388DOI Listing
January 2018

[GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2018].

Authors:

Arerugi 2018 ;67(10):1297-1367

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15036/arerugi.67.1297DOI Listing
January 2018

Food Allergy and Asthma: Is There a Link?

Curr Treat Options Allergy 2018 1;5(4):436-444. Epub 2018 Oct 1.

2Erasmus Medical Center, Department of Internal Medicine, Section of Allergology, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Purpose Of Review: To describe and understand the links and interactions between food allergy and asthma.

Recent Findings: Food allergy and asthma are characterized by an increasing prevalence. Moreover, food allergy and asthma often coexist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40521-018-0185-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244552PMC
October 2018

Allergen-specific IgE and IgG4 patterns among patients with different allergic diseases.

World Allergy Organ J 2018 3;11(1):35. Epub 2018 Dec 3.

1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilova str. 32, Moscow, Russian Federation 119991.

Background: In addition to allergen-specific IgE (sIgE), allergen-specific IgG4 (sIgG4) antibodies are also involved in the immune response resulting from an allergen exposure. The aim of our study was to analyze sIgE and sIgG4 patterns in the most common allergic disorders: bronchial asthma, upper airway disorders and atopic dermatitis.

Methods: In this study a screening analysis of blood serum samples from 673 patients aged from 6 months to 17 years with different allergic entities was performed on microarrays. Read More

View Article

Download full-text PDF

Source
https://waojournal.biomedcentral.com/articles/10.1186/s40413
Publisher Site
http://dx.doi.org/10.1186/s40413-018-0220-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276220PMC
December 2018
2 Reads

Social Networking of Group Two Innate Lymphoid Cells in Allergy and Asthma.

Front Immunol 2018 20;9:2694. Epub 2018 Nov 20.

Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

Allergic diseases including asthma, chronic rhinosinusitis, and atopic dermatitis are common conditions worldwide. While type 2 immune responses induced by T-cells significantly cause allergic inflammation, the recently identified group two innate lymphoid cells (ILC2s) are emerging as critical players in the development of allergy. Upon allergen exposure, ILC2s are rapidly activated by cytokines released by epithelial cells. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02694
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256740PMC
November 2018
2 Reads

Measurement of Nocturnal Scratching in Patients with Pruritus Using a Smartwatch: Initial Clinical Studies with the Itch Tracker App.

Acta Derm Venereol 2018 Dec 6. Epub 2018 Dec 6.

Department of Future Design, Maruho Co Ltd, 531-0071 Osaka, Japan.

Three clinical studies were conducted to test a newly-developed app for smartwatches, which included an algorithm to measure nocturnal scratching using acceleration data. The first study in 5 patients with atopic dermatitis demonstrated high reliability of the app for measurement of scratching compared with video monitoring (positive predictive value 90.2 ± 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3105DOI Listing
December 2018

Glucocorticoid insensitivity by staphylococcal enterotoxin B in keratinocytes of allergic dermatitis is associated with impaired nuclear translocation of the Glucocorticoid Receptor α.

J Dermatol Sci 2018 Nov 26. Epub 2018 Nov 26.

Department of Dermatology and Rheumatology Immunology, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, PR China. Electronic address:

Background: staphylococcal enterotoxin plays an important role in patients with glucocorticoid (GC)-resistant atopic dermatitis (AD), but the exact mechanism is not fully understood.

Objective: The aim of this study was to investigate the mechanisms underlying the ability of staphylococcal enterotoxin B (SEB) to induce steroid insensitivity through impaired nuclear translocation of GRα in keratinocytes.

Methods: The steroid-resistant AD induced by SEB was assessed by analyzing dermatitis score, dermal thickness, scratching behavior, infiltrating cells/HPF, levels of SEB-specific IgE and IgG2a antibody. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2018.11.010DOI Listing
November 2018

[Investigation of the diagnostic value of anti-dense fine speckled 70/lens epithelium derived growth factor p75 autoantibody for autoimmune diseases].

Mikrobiyol Bul 2018 Oct;52(4):413-424

Ankara Training and Research Hospital, Clinic of Medical Microbiology, Ankara, Turkey.

Antinuclear antibodies (ANA) are the autoantibodies that are produced against nuclear antigens in the cell nucleus and/or cytoplasm, and are one of the important diagnostic criteria in systemic autoimmune rheumatic diseases (SARD). Until today, several methods have been developed for detecting ANA's. However, indirect immunofluorescence (IIF) technique, that is also known as one of the oldest methods, is still the most commonly used one. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5578/mb.67385DOI Listing
October 2018

Effect of an insect protein-based diet on clinical signs of dogs with cutaneous adverse food reactions.

Tierarztl Prax Ausg K Kleintiere Heimtiere 2018 Oct 12;46(5):297-302. Epub 2018 Dec 12.

Objective: Edible insects (like mealworms, locusts and crickets) contain energy, protein, fatty acids, minerals and trace elements and have been found to be high quality food sources. They could provide a new food source for patients with adverse food reactions, as well as being of ecological and ethical interest. The aim of this study was to evaluate the effect of a new commercially available, insect protein-based diet on the clinical signs in those dogs via Canine Atopic Dermatitis Lesion Index (CADLI), Pruritus Visual Analogue Scale (PVAS) and coat quality score. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15654/TPK-170833DOI Listing
October 2018
4 Reads

Advances in food allergy in 2017.

J Allergy Clin Immunol 2018 Dec 25;142(6):1719-1729. Epub 2018 Oct 25.

Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; Department of Pediatrics, University of Melbourne, Melbourne, Australia; Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, Australia.

This review highlights research and policy advances in food allergy that were published in 2017 in the Journal and beyond. In 2017, many important studies on the treatment of food allergy were published, bringing us ever closer to a standardized treatment for food allergy. Other important advancements included research into other management strategies, including thresholds for avoidance, management of food allergies in schools, and development of new guidelines for prevention of food allergy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00916749183151
Publisher Site
http://dx.doi.org/10.1016/j.jaci.2018.10.020DOI Listing
December 2018
3 Reads

Analysis of a Large Standardized Food Challenge Data Set to Determine Predictors of Positive Outcome Across Multiple Allergens.

Front Immunol 2018 27;9:2689. Epub 2018 Nov 27.

Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, CA, United States.

Double-blind placebo-controlled food challenges (DBPCFCs) remain the gold standard for the diagnosis of food allergy; however, challenges require significant time and resources and place the patient at an increased risk for severe allergic adverse events. There have been continued efforts to identify alternative diagnostic methods to replace or minimize the need for oral food challenges (OFCs) in the diagnosis of food allergy. Data was extracted for all IRB-approved, Stanford-initiated clinical protocols involving standardized screening OFCs to a cumulative dose of 500 mg protein to any of 11 food allergens in participants with elevated skin prick test (SPT) and/or specific IgE (sIgE) values to the challenged food across 7 sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.02689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277531PMC
November 2018
1 Read

Molecular link between itch and atopic dermatitis.

Proc Natl Acad Sci U S A 2018 Dec 11. Epub 2018 Dec 11.

Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1818879115DOI Listing
December 2018

Health utility scores of atopic dermatitis in US adults.

J Allergy Clin Immunol Pract 2018 Dec 8. Epub 2018 Dec 8.

Oregon Health & Science University, Portland, OR.

Background: The impact of atopic dermatitis (AD) on health related quality of life and health utility in the United States adult population is not well-established.

Objectives: To determine the health utilities and quality of life adjusted years (QALYs) lost in adults with vs. without AD among the US population. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22132198183081
Publisher Site
http://dx.doi.org/10.1016/j.jaip.2018.11.043DOI Listing
December 2018
3 Reads

Pediatric Dermatology - critical approach to the new treatments.

Dermatol Ther 2018 Dec 7:e12801. Epub 2018 Dec 7.

Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health.

The field of pediatric dermatology treatment has been rich in new developments. Several recent therapeutic advances in pediatric dermatology have been made. This review will focus on critical approach to the new treatments for several entities encountered in pediatric dermatology. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.12801
Publisher Site
http://dx.doi.org/10.1111/dth.12801DOI Listing
December 2018
1 Read

Exosomes in chronic inflammatory skin diseases and skin tumors.

Exp Dermatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Exosomes are a type of endosome that can mediate communication between cells and the transport of cellular components such as microRNAs, mRNAs, proteins and DNA. Recently, exosomes have been under investigation for their significant roles in both healthy physiology and disease states. Herein, we review the role of exosomes in chronic inflammatory skin diseases and skin tumors, especially focusing on systemic lupus erythematosus, psoriasis, atopic dermatitis, bullous pemphigoid and melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13857DOI Listing
December 2018
1 Read

Comparison of demographic data, disease severity and response to treatment, between dogs with atopic dermatitis and atopic-like dermatitis: a retrospective study.

Vet Dermatol 2018 Dec 7. Epub 2018 Dec 7.

Department of Veterinary Clinical Sciences and Surgery, Universidade Federal de Minas Gerais, 6627 Antônio Carlos Ave, Belo Horizonte, 31270-901, Brazil.

Background: Limited information is available describing the features of canine atopic-like dermatitis (ALD) compared with atopic dermatitis (AD).

Objectives: To compare demographic data, disease severity and response to therapy between ALD and AD dogs.

Animals: Two hundred and fifty-three atopic dogs with intradermal and serum allergen-specific IgE test results were selected retrospectively. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/vde.12708
Publisher Site
http://dx.doi.org/10.1111/vde.12708DOI Listing
December 2018
3 Reads

JAK Inhibitors for Atopic Dermatitis: An Update.

Am J Clin Dermatol 2018 Dec 7. Epub 2018 Dec 7.

Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, NY, 10029, USA.

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. AD is driven by barrier dysfunction and abnormal immune activation of T helper (Th) 2, Th22, and varying degrees of Th1 and Th17 among various subtypes. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways are involved in signaling of several AD-related cytokines, such as IFN-γ, IL-4, IL-13, IL-31, IL-33, IL-23, IL-22, and IL-17, mediating downstream inflammation and barrier alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0413-2DOI Listing
December 2018
1 Read

Draft Genome Sequences of Five Methicillin-Sensitive Staphylococcus aureus Isolates from Skin Lesions in Patients with Atopic Dermatitis in the Russian Federation.

Microbiol Resour Announc 2018 Oct 4;7(13). Epub 2018 Oct 4.

Department of Genetics and Molecular Biology of Bacteria, N. F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russian Federation, Moscow, Russia.

We present here draft genome sequences of five Staphylococcus aureus strains obtained from children suffering from atopic dermatitis. The strains were determined to be of five different sequence types (sequence type 1 [ST1], ST7, ST8, ST15, and ST101) and carried a unique combination of superantigen-like protein (SSL) and serine protease genes. Read More

View Article

Download full-text PDF

Source
http://genomea.asm.org/lookup/doi/10.1128/MRA.00879-18
Publisher Site
http://dx.doi.org/10.1128/MRA.00879-18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256568PMC
October 2018
2 Reads

Topically applied low-dose calcitriol ameliorates atopic eyelid dermatitis.

JAAD Case Rep 2019 Jan 27;5(1):5-6. Epub 2018 Nov 27.

Department of Dermatology, University of Lübeck, Lübeck, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.09.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262778PMC
January 2019

Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices.

Drugs Context 2018 3;7:212547. Epub 2018 Dec 3.

Department of Pediatrics, The University of Calgary, Alberta Children's Hospital, Calgary, Alberta, Canada.

Background: Eczema or atopic dermatitis (AD) is a common relapsing childhood dermatologic illness. Treatment of AD is primarily topical with emollients and corticosteroid/calcineurin inhibitor, which is efficacious for the majority of patients. However, AD is often complicated and difficult to manage in many Asian cities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7573/dic.212547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281040PMC
December 2018

Clinical characteristics and genetic variation in atopic dermatitis patients with and without allergic contact dermatitis.

Eur J Dermatol 2018 Oct;28(5):637-643

Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea.

In patients with atopic dermatitis (AD), the risk of contact sensitization may be higher as the disrupted skin barrier may increase the penetration of contact allergens. Therefore, it is necessary to screen for concurrent allergic contact dermatitis (ACD) in AD patients. To identify the clinical characteristics and genetic variation in AD patients with concurrent ACD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3422DOI Listing
October 2018

Long-lasting allergic contact dermatitis to methylisothiazolinone misdiagnosed as atopic dermatitis.

Eur J Dermatol 2018 Dec 10. Epub 2018 Dec 10.

CHU Lyon-Sud, Department of Allergology and Clinical Immunology, Lyon, France, Lyon University, Lyon, France, CIRI-INSERM U1111, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3456DOI Listing
December 2018

Rituximab revisited: successful management of severe childhood atopic dermatitis.

Eur J Dermatol 2018 Dec 10. Epub 2018 Dec 10.

Department of Dermatology, Hospital de Santo António dos Capuchos.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3460DOI Listing
December 2018

Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab.

J Investig Allergol Clin Immunol 2018 Dec;28(6):420-421

Allergy Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18176/jiaci.0301DOI Listing
December 2018

Structural Basis of Interleukin-5 Inhibition by the Small Cyclic Peptide AF17121.

J Mol Biol 2018 Dec 7. Epub 2018 Dec 7.

Department of Molecular Plant Physiology and Biophysics, Julius-von-Sachs Institute of the University Wuerzburg, Julius-von-Sachs-Platz 2, D-97082, Wuerzburg, Germany. Electronic address:

Interleukin-5 (IL-5) is a T2 cytokine involved in many aspects of eosinophil life. Eosinophilic granulocytes play a pathogenic role in the progression of atopic diseases, such as allergy, asthma and atopic dermatitis and hypereosinophilic syndromes. Here, eosinophils upon activation degranulate leading to the release of proinflammatory proteins and mediators stored in intracellular vesicles termed granula thereby causing local inflammation, which when persisting leads to tissue damage and organ failure. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00222836183127
Publisher Site
http://dx.doi.org/10.1016/j.jmb.2018.11.029DOI Listing
December 2018
2 Reads

Antibiotic choice and MRSA rate in children who are hospitalized for atopic dermatitis.

Ann Allergy Asthma Immunol 2018 Dec 7. Epub 2018 Dec 7.

Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2018.12.001DOI Listing
December 2018

A Phase 2 Randomized Trial of Apremilast in Patients With Atopic Dermatitis.

J Invest Dermatol 2018 Dec 5. Epub 2018 Dec 5.

Icahn School of Medicine at the Mount Sinai Medical Center, New York, NY, USA.

Background: and Purpose: A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD).

Study Design: and Methods: Patients were randomized to placebo, apremilast 30 mg BID (APR30), or apremilast 40 mg BID (APR40) for 12 weeks. During Weeks 12-24, all patients received APR30 or APR40. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X183290
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.10.043DOI Listing
December 2018
2 Reads

Consensus Statement on the Psychological Needs of Patients With Chronic Inflammatory Skin Diseases.

Actas Dermosifiliogr 2018 Dec 5. Epub 2018 Dec 5.

Servicio de Dermatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.

Objective: To establish recommendations to determine, identify, and manage the psychological and emotional needs of patients with chronic inflammatory skin diseases in clinical practice.

Methods: A guided discussion was held at meeting of a nominal group of expert dermatologists and psychologists on the psychological and emotional needs of patients with chronic inflammatory skin diseases, how to manage these cases, and which referral criteria to employ. Based on the results of the discussion, and with the aid of a patient focus group and a review of the literature, a master document was drawn up with recommendations for discussion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.10.007DOI Listing
December 2018

Chondroitin sulfate inhibits secretion of TNF and CXCL8 from human mast cells stimulated by IL-33.

Biofactors 2018 Dec 6. Epub 2018 Dec 6.

Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, USA.

Glycosaminoglycans (GAGs) are linear, highly negatively charged carbohydrate chains present in connective tissues. Chondroitin sulfate (CS) and heparin (Hep) are also found in the numerous secretory granules of mast cells (MC), tissue immune cells involved in allergic and inflammatory reactions. CS and Hep may inhibit secretion of histamine from rat connective tissue MC, but their effect on human MC remains unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/biof.1464DOI Listing
December 2018
2 Reads